Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zhuang, Yongxian ^a   Chan, Daniel K ^b   Haugrud, Allison B ^a   Miskimins, W Keith ^a  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FRUCTOSE; GALACTOSE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KETOGENIC DIET; MCF 7 CELL LINE; MDAMB231 CELL LINE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVCAR3 CELL LINE; OXIDATIVE PHOSPHORYLATION; PA 1 CELL LINE; SIGNAL TRANSDUCTION; SKBR3 CELL LINE; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASM; PHOSPHORYLATION; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GLUCOSE; GLYCOLYSIS; HYPOGLYCEMIC AGENTS; KETOGENIC DIET; METFORMIN; MICE; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84907583587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108444     Document Type: Article

References (42)

1. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, et al. (2011) Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer.
2. Han L, Ma Q, Li J, Liu H, Li W, et al. (2011) High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One 6: e27074.
3. Sinnett-Smith J, Kisfalvi K, Kui R, Rozengurt E (2013) Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 430: 352-357.
4. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, et al. (2011) Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32: 1381-1387.
5. Lee C, Longo VD (2011) Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 30: 3305-3316.
6. Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, et al. (2011) Metabolic management of brain cancer. Biochim Biophys Acta 1807: 577-594.
7. DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541-549.
8. Rizkalla SW, Elgrably F, Tchobroutsky G, Slama G (1986) Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients. Diabete Metab 12: 219-224.
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
10. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, et al. (2008) In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250.
11. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511.
12. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752.
13. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2009) The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8: 88-96.
14. Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3: 18.
15. Menendez JA, Oliveras-Ferraros C, Cufi S, Corominas-Faja B, Joven J, et al. (2012) Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 11: 2782-2792.
16. Matsuo J, Tsukumo Y, Saito S, Tsukahara S, Sakurai J, et al. (2012) Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivation. Mol Cancer Ther 11: 1082-1091.
17. Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin MJ, et al. (2012) Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res 72: 6257-6267.
18. Zhu Z, Jiang W, Thompson MD, McGinley JN, Thompson HJ (2011) Metformin as an energy restriction mimetic agent for breast cancer prevention. J Carcinog 10: 17.
19. Zhuang Y, Miskimins WK (2011) Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9: 603-615.
20. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, et al. (2006) The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38: 33-42.
21. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, et al. (2000) Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10: 1247-1255.
22. Wu SB, Wei YH (2012) AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases. Biochim Biophys Acta 1822: 233-247.
23. Andrade BM, Cazarin J, Zancan P, Carvalho DP (2012) AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid 22: 1063-1068.
24. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U (2013) Metformin-an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med 54: 252-258.
25. Smith TA, Zanda M, Fleming IN (2013) Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase. Nucl Med Biol 40: 858-864.
26. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (2007) Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 97: 539-547.
27. Reitzer LJ, Wice BM, Kennell D (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669-2676.
28. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, et al. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228.
29. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 Pt 3: 607-614.
30. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, et al. (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475.
31. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, et al. (2011) Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117: 2926-2938.
32. Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, et al. (2011) Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res 31: 421-426.
33. Saito S, Furuno A, Sakurai J, Sakamoto A, Park HR, et al. (2009) Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. Cancer Res 69: 4225-4234.
34. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, et al. (2013) LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23: 143-158.
35. Bonini MG, Gantner BN (2013) The multifaceted activities of AMPK in tumor progression-why the "one size fits all" definition does not fit at all? IUBMB Life 65: 889-896.
36. Wu H, Ding Z, Hu D, Sun F, Dai C, et al. (2011) Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol.
37. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev: CD002967.
38. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, et al. (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4: 5.
39. Oleksyszyn J (2011) The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug metformin, as a potential anti-cancer therapy. Med Hypotheses 77: 171-173.
40. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
41. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, et al. (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192.
42. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.